Video
Author(s):
Lori A. Leslie, MD, and Andre H. Goy, MD, share strategies for when CAR T-cell therapy is not an option.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Lori A. Leslie, MD, assistant professor, Hackensack Meridian School of Medicine, director, Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs, John Theurer Cancer Center, and Andre H. Goy, MD, physician in chief of the Hackensack Meridian Health Oncology Care Transformation Services, chairman and chief physician officer at John Theurer Cancer Center at Hackensack University Medical Center, and Lymphoma Division Chief at the John Theurer Cancer Center, share strategies for when CAR T-cell therapy is not an option.
The patient population that is ineligible for CAR T-cell therapy is shrinking because of improved toxicity management and intervention, Leslie says. Now, referring providers may be surprised by which patients are eligible for CAR T-cell therapy. As such, it is important to evaluate patients at a CAR T-cell therapy center. However, for patients who are not eligible for CAR T-cell therapy, more options have become available. For example, in diffuse large B-cell lymphoma, agents such as tafasitamab-cxix (Monjuvi), selinexor (Xpovio), and loncastuximab tesirine-lpyl (Zynlonta) are approved for use. Currently, these agents are not curative, although they have shown high response rates, Goy says.
For patients who are eligible for both CAR T-cell therapy and novel agents, treatment is typically sequenced such that novel agents are used following CAR T-cell therapy failure, Leslie says. However, regimens that incorporate novel agents into up-front treatment are also being explored. For example, the phase 3 POLARIX trial (NCT03274492) evaluated the addition of the antibody-drug conjugate polatuzumab vedotin-piiq (Polivy) to rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone. These agents are also being incorporated into existing treatment regimens as a bridge to CAR T-cell therapy, Leslie says.
In terms of investigational therapeutics, bispecific T-cell engagers have garnered significant excitement and have shown encouraging responses post CAR T-cell therapy, Leslie says. However, because these agents are more easily administered than CAR T-cell therapy, a key question is whether these agents will replace CAR T-cell therapy in certain scenarios, Leslie concludes.
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management
TERZO Trial Seeks to Validate Duvelisib as an Effective Targeted Treatment in TFH Nodal T-Cell Lymphoma
Mevrometostat Plus Enzalutamide Improves rPFS vs Enzalutamide in Metastatic CRPC
Kimberly Stegmaier Named as Pediatric Oncology Chair at Dana-Farber
2 Commerce Drive
Cranbury, NJ 08512